Tanja E. Argillander
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Tanja E. Argillander has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
B.C. van Munster
University of Groningen, University Medical Center Groningen, University Center of Geriatric Medicine, Groningen, the Netherlands
4 shared publicationsP. van Duijvendijk
Department of Surgery, Gelre Hospitals, Apeldoorn, The Netherlands
4 shared publicationsChristianne J. Buskens
Department of Surgery, Academic Medical Center, Amsterdam, the Netherlands
3 shared publicationsEmma R.J. Bruns
3 shared publicationsH.J. van der Zaag-Loonen
University of Groningen, University Medical Center Groningen, University Center of Geriatric Medicine, Groningen, the Netherlands
3 shared publicationsPeter van Duijvendijk
Department of Surgery, Gelre Hospitals, Apeldoorn, The Netherlands
3 shared publications
Latest Publications
- 19 May 2022
- Published by Elsevier in Journal of Geriatric Oncology
- Vol. 13 (6) , 796-802
Predictive value of selected geriatric parameters for postoperative outcomes in older patients with rectal cancer – A multicenter cohort study
- 19 May 2022
- Published by Elsevier in Journal of Geriatric Oncology
- Vol. 13 (6) , 796-802
Predictive value of selected geriatric parameters for postoperative outcomes in older patients with rectal cancer – A multicenter cohort study
- Open Access
- 16 May 2022
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 48 (9) , 1882-1894
Outcomes of surgical treatment of non-metastatic gastric cancer in patients aged 70 and older: A systematic review and meta-analysis
- 16 May 2022
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 48 (9) , 1882-1894
Open AccessOutcomes of surgical treatment of non-metastatic gastric cancer in patients aged 70 and older: A systematic review and meta-analysis
- Open Access
- 24 March 2022
- Published by Elsevier in Journal of Geriatric Oncology
- Vol. 13 (6) , 888-891
The predictive value of preoperative frailty screening for postoperative outcomes in older patients undergoing surgery for non-metastatic colorectal cancer
- 24 March 2022
- Published by Elsevier in Journal of Geriatric Oncology
- Vol. 13 (6) , 888-891
Open AccessThe predictive value of preoperative frailty screening for postoperative outcomes in older patients undergoing surgery for non-metastatic colorectal cancer
- Open Access
- 1 March 2022
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 48 (3) , 570-581
Preoperative physical performance as predictor of postoperative outcomes in patients aged 65 and older scheduled for major abdominal cancer surgery: A systematic review
- 1 March 2022
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 48 (3) , 570-581
Open AccessPreoperative physical performance as predictor of postoperative outcomes in patients aged 65 and older scheduled for major abdominal cancer surgery: A systematic review
- 1 May 2019
- Published by Wolters Kluwer Health in American Journal of Physical Medicine & Rehabilitation
- Vol. 98 (5) , 399-406
Fit4SurgeryTV At-home Prehabilitation for Frail Older Patients Planned for Colorectal Cancer Surgery
Objective: The preoperative phase is a potential window of opportunity. Although frail elderly patients are known to be more prone to postoperative complications, they are often not considered capable of accomplishing a full prehabilitation program. The aim of this study was to assess the feasibility of Fit4SurgeryTV, an at-home prehabilitation program specifically designed for frail older patients with colorectal cancer. Design: The Fit4SurgeryTV program consisted of a daily elderly adapted computer-supported strength training workout and two protein-rich meals. Frail patients 70 yrs or older with colorectal cancer were included. The program was considered feasible if 80% of the patients would be able to complete 70% of the program. Results: Fourteen patients (median age, 79 yrs; 5 males) participated. At baseline, 86% patients were physically impaired and 64% were at risk for malnourishment. The median duration of the program was 26 days. The program was feasible as patients followed the exercises for 6 (86%) of 7 days and prepared the recipes 5 (71%) of 7 d/wk. Patients specifically appreciated at-home exercises. Conclusions: This study showed that at-home prehabilitation in frail older patients with colorectal cancer is feasible. As a result, patients might be fitter for surgery and might recover faster. The perioperative period could serve as a pivotal time point in reverting complications of immobility.
- 1 May 2019
- Published by Wolters Kluwer Health in American Journal of Physical Medicine & Rehabilitation
- Vol. 98 (5) , 399-406
Fit4SurgeryTV At-home Prehabilitation for Frail Older Patients Planned for Colorectal Cancer Surgery
Objective: The preoperative phase is a potential window of opportunity. Although frail elderly patients are known to be more prone to postoperative complications, they are often not considered capable of accomplishing a full prehabilitation program. The aim of this study was to assess the feasibility of Fit4SurgeryTV, an at-home prehabilitation program specifically designed for frail older patients with colorectal cancer. Design: The Fit4SurgeryTV program consisted of a daily elderly adapted computer-supported strength training workout and two protein-rich meals. Frail patients 70 yrs or older with colorectal cancer were included. The program was considered feasible if 80% of the patients would be able to complete 70% of the program. Results: Fourteen patients (median age, 79 yrs; 5 males) participated. At baseline, 86% patients were physically impaired and 64% were at risk for malnourishment. The median duration of the program was 26 days. The program was feasible as patients followed the exercises for 6 (86%) of 7 days and prepared the recipes 5 (71%) of 7 d/wk. Patients specifically appreciated at-home exercises. Conclusions: This study showed that at-home prehabilitation in frail older patients with colorectal cancer is feasible. As a result, patients might be fitter for surgery and might recover faster. The perioperative period could serve as a pivotal time point in reverting complications of immobility.
- 1 March 2019
- Published by Wolters Kluwer Health in American Journal of Physical Medicine & Rehabilitation
- Vol. 98 (3) , 231-238
Improving Outcomes in Oncological Colorectal Surgery by Prehabilitation
Introduction: The cornerstone in the treatment of colorectal cancer is surgery. A surgical event poses a significant risk of decreased functional decline and impaired health-related quality of life. Prehabilitation is defined as the multimodal preoperative enhancement of a patient's condition. It may serve as a strategy to improve postoperative outcomes. Prehabilitation requires a multidisciplinary effort of medical health care professionals and a behavioral change of the patient.Methods: The goal of prehabilitation is threefold: (1) to reduce postoperative complications, (2) to enhance and accelerate the recovery of the patient, and (3) to improve overall quality of life. In this article, we introduce the FIT model illustrating a possible framework toward the implementation of both evidence-based and tailor-made prehabilitation for patients undergoing surgery for colorectal cancer.Results: The model is composed of three pillars: “facts” (how to screen patients and evidence on what content to prescribe), “integration” (data of own questionnaires assessing motivation of patients and specialists), and finally “tools” (which outcome measurements to use).Discussion: Developing implementable methods and defining standardized outcome instruments will help establish a solid base for patient-centered prehabilitation programs. Any party introducing prehabilitation requiring multidisciplinary teamwork and behavioral change can potentially use this framework.
- 1 March 2019
- Published by Wolters Kluwer Health in American Journal of Physical Medicine & Rehabilitation
- Vol. 98 (3) , 231-238
Improving Outcomes in Oncological Colorectal Surgery by Prehabilitation
Introduction: The cornerstone in the treatment of colorectal cancer is surgery. A surgical event poses a significant risk of decreased functional decline and impaired health-related quality of life. Prehabilitation is defined as the multimodal preoperative enhancement of a patient's condition. It may serve as a strategy to improve postoperative outcomes. Prehabilitation requires a multidisciplinary effort of medical health care professionals and a behavioral change of the patient.Methods: The goal of prehabilitation is threefold: (1) to reduce postoperative complications, (2) to enhance and accelerate the recovery of the patient, and (3) to improve overall quality of life. In this article, we introduce the FIT model illustrating a possible framework toward the implementation of both evidence-based and tailor-made prehabilitation for patients undergoing surgery for colorectal cancer.Results: The model is composed of three pillars: “facts” (how to screen patients and evidence on what content to prescribe), “integration” (data of own questionnaires assessing motivation of patients and specialists), and finally “tools” (which outcome measurements to use).Discussion: Developing implementable methods and defining standardized outcome instruments will help establish a solid base for patient-centered prehabilitation programs. Any party introducing prehabilitation requiring multidisciplinary teamwork and behavioral change can potentially use this framework.
- Open Access
- 1 October 2018
- Published by Wiley in United European Gastroenterology Journal
- Vol. 6 (8) , 1215-1222
Features of incident colorectal cancer in Lynch syndrome
Background and objective: Despite intensive colonoscopic surveillance, a substantial proportion of Lynch syndrome (LS) patients develop colorectal cancer (CRC). The aim of this study was to characterize incident CRC in LS patients.Methods: All patients diagnosed with incident CRC after start of colonoscopic surveillance were identified in the Dutch LS Registry of 905 patients. A retrospective analysis of patient records was carried out for patient characteristics, survival, CRC characteristics and findings of previous colonoscopy.Results: Seventy‐one patients (7.8%) were diagnosed with incident CRC. Median interval between incident CRC diagnosis and previous colonoscopy was 23.8 (range 6.7–45.6) months. Median tumor diameter was 2.5 cm, and 17% of the tumors were sessile or flat. Most patients (83%) had no lymph node metastases. There was no association between tumor size and colonoscopy interval or lymph node status. Most patients (65%) had no adenomas during previous colonoscopy. Two patients (2.8%) eventually died from metastatic CRC.Conclusion: The high frequency of incident CRC in LS likely results from several factors. Our findings lend support to the hypothesis of fast conversion of adenomas to CRC, as 65% of patients had no report of polyps during previous colonoscopy. High‐quality colonoscopies are essential, especially as tumors and adenomas are difficult to detect because of their frequent non‐polypoid appearance. Early detection due to surveillance as well as the indolent growth of CRC, as demonstrated by the lack of lymph node metastases, contributes to the excellent survival observed.
- 1 October 2018
- Published by Wiley in United European Gastroenterology Journal
- Vol. 6 (8) , 1215-1222
Open AccessFeatures of incident colorectal cancer in Lynch syndrome
Background and objective: Despite intensive colonoscopic surveillance, a substantial proportion of Lynch syndrome (LS) patients develop colorectal cancer (CRC). The aim of this study was to characterize incident CRC in LS patients.Methods: All patients diagnosed with incident CRC after start of colonoscopic surveillance were identified in the Dutch LS Registry of 905 patients. A retrospective analysis of patient records was carried out for patient characteristics, survival, CRC characteristics and findings of previous colonoscopy.Results: Seventy‐one patients (7.8%) were diagnosed with incident CRC. Median interval between incident CRC diagnosis and previous colonoscopy was 23.8 (range 6.7–45.6) months. Median tumor diameter was 2.5 cm, and 17% of the tumors were sessile or flat. Most patients (83%) had no lymph node metastases. There was no association between tumor size and colonoscopy interval or lymph node status. Most patients (65%) had no adenomas during previous colonoscopy. Two patients (2.8%) eventually died from metastatic CRC.Conclusion: The high frequency of incident CRC in LS likely results from several factors. Our findings lend support to the hypothesis of fast conversion of adenomas to CRC, as 65% of patients had no report of polyps during previous colonoscopy. High‐quality colonoscopies are essential, especially as tumors and adenomas are difficult to detect because of their frequent non‐polypoid appearance. Early detection due to surveillance as well as the indolent growth of CRC, as demonstrated by the lack of lymph node metastases, contributes to the excellent survival observed.
- 1 June 2018
- Published by Wolters Kluwer Health in Stroke
- Vol. 49 (6) , 1531-1533
Effect of Antihypertensive Medication on Cerebral Small Vessel Disease
Background and Purpose—: Hypertension is an important risk factor for cerebral small vessel disease. We aimed to study the effect of antihypertensive medication (AHM) on the progression of cerebral small vessel disease. Methods—: We performed a systematic literature search of electronic databases up to January 30, 2017, for randomized controlled trials on the effect of AHM on ≥1 cerebral small vessel disease magnetic resonance imaging markers (ie, white matter hyperintensities, lacunes, microbleeds, enlarged perivascular spaces, acute small subcortical infarcts, and brain atrophy) after ≥1 year. We performed a random-effects meta-analysis using standardized mean difference. Results—: We included 4 trials, including patients with stroke, with diabetes mellitus, and people ≥70 years of age. Patients in the AHM group had less progression of white matter hyperintensity during 28 to 47 months (standardized mean difference, −0.19; 95% confidence interval, −0.32 to −0.06; I 2 =20%; n=1369). Two trials reported on progression of brain atrophy with conflicting results. None of the trials reported on other cerebral small vessel disease markers. Conclusions—: AHM has a protective effect on the progression of white matter hyperintensities, but no effect on brain atrophy. There are no trials on the effect of AHM on lacunes, microbleeds, enlarged perivascular spaces, or acute small subcortical infarcts.
- 1 June 2018
- Published by Wolters Kluwer Health in Stroke
- Vol. 49 (6) , 1531-1533
Effect of Antihypertensive Medication on Cerebral Small Vessel Disease
Background and Purpose—: Hypertension is an important risk factor for cerebral small vessel disease. We aimed to study the effect of antihypertensive medication (AHM) on the progression of cerebral small vessel disease. Methods—: We performed a systematic literature search of electronic databases up to January 30, 2017, for randomized controlled trials on the effect of AHM on ≥1 cerebral small vessel disease magnetic resonance imaging markers (ie, white matter hyperintensities, lacunes, microbleeds, enlarged perivascular spaces, acute small subcortical infarcts, and brain atrophy) after ≥1 year. We performed a random-effects meta-analysis using standardized mean difference. Results—: We included 4 trials, including patients with stroke, with diabetes mellitus, and people ≥70 years of age. Patients in the AHM group had less progression of white matter hyperintensity during 28 to 47 months (standardized mean difference, −0.19; 95% confidence interval, −0.32 to −0.06; I 2 =20%; n=1369). Two trials reported on progression of brain atrophy with conflicting results. None of the trials reported on other cerebral small vessel disease markers. Conclusions—: AHM has a protective effect on the progression of white matter hyperintensities, but no effect on brain atrophy. There are no trials on the effect of AHM on lacunes, microbleeds, enlarged perivascular spaces, or acute small subcortical infarcts.